“Dream Come True”: Study suggests drug could extend women’s fertility by five years. The Guardian

Rapamycin, originally developed as an immunosuppressant, has been explored for its potential to extend lifespan and delay aging. The Guardian has reported on several studies investigating its effects:

Women’s Health and Reproductive Aging
In July 2024, researchers at Columbia University announced preliminary results from a clinical trial exploring Rapamycin for women’s health. The study suggests that rapamycin could delay menopause by approximately 20%, potentially reducing health risks associated with aging ovaries. These findings highlight rapamycin’s potential in reproductive aging and its role as a therapeutic option for aging ovaries. The study is part of an ongoing rapamycin fertility extension study aimed at improving reproductive health in later life.

Dogs as Models for Human Aging
In December 2024, The Guardian highlighted research involving dogs to study longevity drugs like rapamycin. The Dog Aging Project is testing rapamycin to determine if it can extend dogs’ healthy lifespan, with the hope that findings could inform human aging studies.

Immune System Rejuvenation
In July 2018, The Guardian reported on trials of anti-aging drugs, including rapamycin, aimed at rejuvenating the immune system. These drugs work by inhibiting the mTOR pathway, which is involved in aging processes.

While these studies are promising, Rapamycin for women’s health and other reproductive applications remain experimental. Further research is necessary to fully understand its efficacy and safety in humans.